Publicaciones en colaboración con investigadores/as de University of California, Irvine (5)

2022

  1. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

    Blood, Vol. 140, Núm. 5, pp. 419-437

2021

  1. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

  2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

2020

  1. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    European Journal of Cancer, Vol. 133, pp. 120-130

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204